Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Dade Behring Acquires Rights to Cardiac Marker

By HospiMedica staff writers
Posted on 20 Feb 2003
A non-exclusive license under patent rights to develop, manufacture, and market immunoassays that detect a key marker of congestive heart failure (CHF) has been granted to Dade Behring (Deerfield, IL, USA) by Roche Diagnostics (Basel, Switzerland). More...
The marker is NT-proBNP (N-terminal prohormone brain natriuretic peptide).

BNP is secreted by the left ventricle when the heart is unable to pump blood efficiently. BNP dilates blood vessels and promotes sodium and water loss, reducing fluid load on the heart. Synthetic BNP (nesiritide) does not necessarily allow doctors to differentiate between elevated BNP levels due to drug treatment or due to ventricular dysfunction. In contrast, proBNP measures a hormone released when BNP is cleaved from its precursor, proBNP.

Elevated plasma NT-proBNP indicates the presence of heart failure and provides information about its severity. Also, NT-proBNP levels can help doctors identify left ventricular dysfunction, thereby allowing them to differentiate between heart failure and lung disorders with similar symptoms.

"This license enables Dade Behring, a market leader in clinical diagnostics for cardiac disease, to access an important new marker for use in the early detection and treatment of CHF,” said Jim Reid-Anderson, chairman, president, and CEO of Dade Behring.





Related Links:
Dade Behring
Roche

Gold Member
Flocked Fiber Swabs
Puritan® Patented HydraFlock®
New
Gold Member
Automatic Hematology Analyzer
CF9600
New
Electrolyte Analyzer
CBS-4000 (CBS-400)
New
Clinical Informatics Platform
CLARION™
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: The device contains specific antibodies that capture the primary biomarker of pancreatic cancer. The binding of these antibodies alters the distribution of electrical charges on the electrode surface. The sensor then translates this variation into a measurable capacitance signal (photo courtesy of Gabriella Soares / IFSC-USP)

Rapid Biosensor Detects Pancreatic Cancer Biomarker for Early Detection

Pancreatic cancer is frequently identified only after it has progressed because early disease is typically asymptomatic, and survival remains extremely poor once advanced. Conventional laboratory assays... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.